PCSA

Processa Pharmaceuticals Inc - Terminates Licensing Agreement With Ocuphire Pharma - SEC Filing

时间：2025-07-01 21:12:45 市场：综合美股

关联： PCSA

Processa Pharmaceuticals Inc - Purchase Price per Share $0.615 for Institutional Investors, $0.7975 for CEO and Board

时间：2025-01-28 09:30:02 市场：美股综合

关联： PCSA

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced at-the-Market Under Nasdaq Rules

时间：2025-01-28 09:30:02 市场：美股综合

关联： PCSA

Processa Pharmaceuticals Files for Public Offering of up to 9.4 Mln Shares of Common Stock and Accompanying Common Warrants

时间：2025-01-16 19:26:43 市场：美股综合

关联： PCSA

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of Ngc-Cap in Metastatic Breast Cancer

时间：2024-10-03 04:05:00 市场：美股综合

关联： PCSA